Nonclassical Estrogen Signaling

Pathway selective ER ligands have been reported that selectively inhibit nuclear factor kB (NF-kB) mediated gene expression [71], Since NF-kB is a pivotal regulator of pro-inflammatory gene expression, ligands that selectively inhibit the NF-kB pathway could be developed for the treatment of chronic inflammatory diseases such as arthritis, atherosclerosis, sepsis, and inflammatory bowel disease 

The discovery of structurally novel SERMs continues to provide insights into the complexities of ER signaling. Chemical tools have been developed to test clinical hypotheses that SERMs may be used to treat a variety of diseases ranging from 

Metabolic Disease Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA 

Annual Reports in Medicinal Chemistry, Volume 42 2007 Elsevier Inc. 

---